Favipiravir for treating COVID-19
CONCLUSIONS: The low- to very low-certainty evidence means that we do not know whether favipiravir is efficacious in people with COVID-19 illness, irrespective of severity or admission status. Treatment with favipiravir may result in an overall increase in the incidence of adverse events but may not result in serious adverse events.PMID:38314855 | PMC:PMC10840071 | DOI:10.1002/14651858.CD015219.pub2 (Source: Cochrane Database of Systematic Reviews)
Source: Cochrane Database of Systematic Reviews - February 5, 2024 Category: General Medicine Authors: Pritish Korula Hanna Alexander Jisha Sara John Richard Kirubakaran Bhagteshwar Singh Prathap Tharyan Priscilla Rupali Source Type: research
Nirmatrelvir/ritonavir and pharmacovigilance data
(Source: International Journal of Tuberculosis and Lung Disease)
Source: International Journal of Tuberculosis and Lung Disease - February 3, 2024 Category: Respiratory Medicine Authors: Lassan, S. Gocova, M. Solovic, I. Tesar, T. Motesicka, Z. Lassanova, M. Tags: LETTERS Source Type: research
Physicochemical interaction of rifampicin and ritonavir-lopinavir solid dispersion: an in-vitro and ex-vivo investigation
CONCLUSION: RIF, RTV and LOP in presence of each other on pH-shift, results in co-precipitation in the amorphous form (miscible) which leads to reduction in the highest attainable degree of supersaturation. This reduction corresponds to the mole fraction of the RIF, RTV and LOP within the studied system. These findings suggest that the concomitant administration of these drugs may lead to physicochemical interactions and possible ineffective therapy.PMID:38305806 | DOI:10.1080/03639045.2024.2309508 (Source: Drug Development and Industrial Pharmacy)
Source: Drug Development and Industrial Pharmacy - February 2, 2024 Category: Drugs & Pharmacology Authors: Athira R Nair Sai Krishna Anand Vullendula Dani Lakshman Yarlagadda Brahmam Bheemisetty Swapnil J Dengale Krishnamurthy Bhat Source Type: research
What the Latest Research Says About Paxlovid
This Medical News story examines the latest information about rebound, treatment eligibility, optimal dosing, and other questions related to nirmatrelvir-ritonavir for treating COVID-19. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - January 31, 2024 Category: General Medicine Source Type: research
Effectiveness and safety of nirmatrelvir-ritonavir in kidney transplant recipients with severe kidney dysfunction infected with COVID-19
In this study, we focus on kidney transplant patients and document and analyze the experiences of using NR in individuals with severe kidney dysfunction. This was a retrospective multicenter study that included transplant recipients hospitalized for COVID-19 in five major tertiary hospitals in China from December 2022 to June 2023. The outcomes consisted of the disease progression rate by day 28, individual disease progression events, safety outcomes, information on adverse events (AEs), and the blood drug concentrations of immunosuppressants. Data were presented with descriptive statistics. All analyses were performed usi...
Source: Antimicrobial Agents and Chemotherapy - January 30, 2024 Category: Microbiology Authors: Hui Yang Xin Yu Wenjing Hou Xiangduan Liu Jiaojiao Chen Ying Zhang Ying Wang Ying Zhu Qing Qian Kuifen Ma Zhuoling An Source Type: research
The Efficacy and Safety of Nirmatrelvir/Ritonavir Against COVID-19 in Elderly Patients
(Source: International Journal of General Medicine)
Source: International Journal of General Medicine - January 30, 2024 Category: General Medicine Tags: International Journal of General Medicine Source Type: research
A Phase-IV Non-interventional Study to Assess Virological Effectiveness, Safety, and Tolerability of DTG-based Antiretroviral Therapy in HIV-1 Infected Indian Persons Living with HIV
CONCLUSION: Our results from a large Indian cohort indicate a favourable virological and metabolic response, with good tolerance of DTG-based ART at 24 weeks.PMID:38284697 | DOI:10.2174/011570162X264021231108010324 (Source: Current HIV Research)
Source: Current HIV Research - January 29, 2024 Category: Infectious Diseases Authors: Kuldeep Ashta Sumit Arora Rajesh Khanna Anirudh Anilkumar Nishant Raman Charu Mohan Source Type: research
Real-world prescription of anti-COVID-19 drugs in hospitalized patients with COVID-19 in Japan
Conclusions and relevanceThis study revealed the real-world situation of anti-COVID-19 drug prescriptions in hospitalized COVID-19 patients in Japan. A prescribed drug would depend on the latest scientific evidence, such as efficacy, safety, and approval status, at the time of prescription. Understanding the prescription of anti-COVID-19 drugs will be important for providing the most up-to-date treatments to patients and evaluating the benefit and/or risk of anti-COVID-19 drugs based on the utilization of an electronic medical record database. (Source: PLoS One)
Source: PLoS One - January 26, 2024 Category: Biomedical Science Authors: Haruka Shida Source Type: research
Obesity and its Relationship with Covid-19: A Review of the Main Pharmaceutical Aspects
Curr Pharm Biotechnol. 2024 Jan 22. doi: 10.2174/0113892010264503231108070917. Online ahead of print.ABSTRACTImportant physiological changes are observed in patients with obesity, such as intestinal permeability, gastric emptying, cardiac output, and hepatic and renal function. These differences can determine variations in the pharmacokinetics of different drugs and can generate different concentrations at the site of action, which can lead to sub therapeutic or toxic concentrations. Understanding the physiological and immunological processes that lead to the clinical manifestations of COVID-19 is essential to correlate ob...
Source: Current Pharmaceutical Biotechnology - January 23, 2024 Category: Biotechnology Authors: Katharine Hodel Ananda Fonseca Islania Barbosa Caio Medina Brenda Alves Carine Maciel Daniel Nascimento Gessualdo Oliveira-Junior Lorena Pedreira Monielly de Souza Ana Leonor Godoy Source Type: research
Population Pharmacokinetics of Pediatric Lopinavir/Ritonavir Oral Pellets in Children Living with HIV in Africa
Clin Pharmacol Ther. 2024 Jan 21. doi: 10.1002/cpt.3174. Online ahead of print.ABSTRACTAntiretroviral therapy for children living with HIV (CLHIV) under 3 years of age commonly includes lopinavir/ritonavir (LPV/r). However, the original liquid LPV/r formulation has taste and cold storage difficulties. To address these challenges, LPV/r oral pellets have been developed. These pellets can be mixed with milk or food for administration and do not require refrigeration. We developed the population pharmacokinetic (PK) model and assessed drug exposure of LPV/r oral pellets administered twice daily to CLHIV per World Health Organ...
Source: Clinical Pharmacology and Therapeutics - January 22, 2024 Category: Drugs & Pharmacology Authors: Suthunya Chupradit Dalton C Wamalwa Elizabeth Maleche-Obimbo Adeodata R Kekitiinwa Juliet Mwanga-Amumpaire Elizabeth A Bukusi Winstone M Nyandiko Joseph K Mbuthia Alistair Swanson DNDi Clinical Team Tim R Cressey Baralee Punyawudho Victor Musiime LIVING S Source Type: research
Nirmatrelvir-ritonavir (Paxlovid) Access, Use, and Eligibility Among Adults with COVID-19 in Los Angeles County: The LA Pandemic Surveillance Cohort Study
(Source: Journal of General Internal Medicine)
Source: Journal of General Internal Medicine - January 22, 2024 Category: Internal Medicine Source Type: research
Red light-emitting diode therapy minimizes the functional deleterious effects of the antiretroviral ritonavir on osteoblasts in vitro
ConclusionIn conclusion, photobiostimulation with red LED at 625 nm was associated with improved beneficial biological effects as a potential inducer of osteogenic activity on RTV-affected cells. This is the first study that investigated the benefits of red LED irradiation over ARV-treated in vitro osteoblasts. (Source: Lasers in Medical Science)
Source: Lasers in Medical Science - January 17, 2024 Category: Laser Surgery Source Type: research
Cancers, Vol. 16, Pages 379: COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant
In conclusion, COVID-19 mortality in HM patients has decreased considerably in the Omicron period; however, mortality in hospitalized HM patients remains high. Specific studies should be undertaken to test new treatments and preventive interventions in HM patients. (Source: Cancers)
Source: Cancers - January 16, 2024 Category: Cancer & Oncology Authors: Joaqu ín Martínez-López Javier de la Cruz Rodrigo Gil-Manso V íctor Jiménez Yuste Jos é María Aspa-Cilleruelo Cristian Escolano Escobar Javier L ópez-Jiménez Rafael Duarte Cristina Jacome Yerovi Jos é-Ángel Hernández-Rivas Regina Herr áez Kei Tags: Article Source Type: research
Annals On Call - COVID-19 Rebound After Nirmatrelvir-Ritonavir Treatment
Ann Intern Med. 2024 Jan;177(1):eA230002. doi: 10.7326/A23-0002.NO ABSTRACTPMID:38224601 | DOI:10.7326/A23-0002 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - January 15, 2024 Category: Internal Medicine Authors: Robert M Centor Myron S Cohen Source Type: research
